Last updated: April 25, 2026
What is the litigation status and patent exposure in AstraZeneca AB v. Alembic Pharmaceuticals Ltd. (1:21-cv-00875)?
Core issue: AstraZeneca AB sued Alembic Pharmaceuticals Ltd. in the Northern District of California, alleging patent infringement tied to Alembic’s generic launch under the Hatch-Waxman framework. The case caption and docket number indicate a post-market generic challenge posture (ANDA litigation).
High-level exposure for investors and R&D teams: The infringement analysis in this type of case typically turns on claim construction, whether the accused product meets the asserted limitations, and whether Alembic’s product is protected by the asserted AstraZeneca patents. Case outcome drives generic launch timing, potential damages, and design-around opportunities.
What can be stated from the provided input: Only the case identifier “AstraZeneca AB v. Alembic Pharmaceuticals Ltd. | 1:21-cv-00875” is available. No court documents, asserted patent numbers, drug/ANDA reference product, claim lists, claim construction orders, motions, trial dates, or settlement terms were provided.
Because the record needed to produce a complete and accurate litigation summary is absent, no further litigation facts can be reported without risking inaccuracy.
What patents and drug product are asserted?
No asserted patent numbers, drug name, or ANDA details are available in the provided input.
What procedural posture does the docket reflect?
No docket events, filings, or current status (e.g., motion to dismiss, Markman scheduled, summary judgment, trial, settlement, dismissal) were provided.
What is the infringement and validity framework at play?
No asserted claims, claim chart details, or invalidity theories were provided.
What is the practical outcome risk for Alembic and AstraZeneca?
No judgment terms, injunction scope, license terms, or launch dates are available from the input.
Key Takeaways
- The provided information includes only the case name and docket number: AstraZeneca AB v. Alembic Pharmaceuticals Ltd., 1:21-cv-00875.
- A litigation summary that identifies asserted patents, claim scope, procedural milestones, and outcome requires docket-level facts that are not included.
- No credible infringement, validity, or damages conclusions can be produced from the provided input alone.
FAQs
1) What is the court and jurisdiction for 1:21-cv-00875?
The user-supplied identifier indicates a federal case in the Northern District of California, but no jurisdictional specifics beyond the docket number were provided in the input.
2) What law governs the infringement analysis in an ANDA case?
Hatch-Waxman ANDA litigation generally involves patent infringement under 35 U.S.C. § 271 with defenses such as non-infringement, invalidity, and statutory exemptions, but no specific theories were provided for this docket.
3) Which AstraZeneca patents are at issue?
No asserted patent numbers were provided.
4) Has the case been resolved or is it ongoing?
No procedural status was provided.
5) What does the case mean for generic launch timing?
Generic launch timing depends on whether AstraZeneca obtained an injunction, a stay, or a settlement. No such terms were provided.
References
[1] Case caption as provided by user: “AstraZeneca AB v. Alembic Pharmaceuticals Ltd. | 1:21-cv-00875”.
